Covestro (1COV) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
FY 2025 marked by adverse economic conditions, with sales declining to €12.9bn, mainly due to lower prices and unfavorable FX impacts.
EBITDA fell 30.9% year-over-year to €740m, within guidance, as margin pressure persisted.
Net income was negative at -€644m, reflecting significantly lower EBIT and impairment losses.
Strategic partnership with XRG successfully commenced, and two bolt-on acquisitions strengthened the Solutions & Specialties segment.
Financial highlights
Sales dropped 8.7% year-over-year, primarily due to a 5.2% price decline and 2.6% FX impact.
EBITDA decreased to €740m from €1,071m, mainly due to negative pricing delta and restructuring costs.
Free operating cash flow (FOCF) was negative at -€283m, driven by lower EBITDA.
Earnings per share declined to -€3.39 from -€1.41 year-over-year.
Outlook and guidance
FY 2026 EBITDA expected around 2025 level; FOCF and ROCE anticipated to improve significantly.
GHG emissions (scope 1 and 2) guided between 3.9 and 4.5m tons for 2026.
Mark-to-market EBITDA for FY 2026 projected at approximately €0.8bn.
Latest events from Covestro
- FY 2025 saw lower sales and earnings, but transformation and climate targets remain on track.1COV
Investor presentation26 Feb 2026 - EBITDA fell 30.9% to €740m as strategic actions and XRG partnership offset weak demand.1COV
Q4 2025 (Media)26 Feb 2026 - Sales and EBITDA fell in Q3 2025, with guidance cut and acquisitions advancing.1COV
Q3 20253 Feb 2026 - Volume growth offset by lower prices; EBITDA fell and guidance narrowed as ADNOC talks progress.1COV
Q2 20242 Feb 2026 - €62/share offer and €1.17bn capital boost support growth, sustainability, and governance.1COV
Investor Update20 Jan 2026 - Q3 volume growth offset price declines; FY 2024 outlook narrowed amid margin pressure.1COV
Q3 202418 Jan 2026 - Stable EBITDA and volume growth offset price declines; XRG takeover and STRONG program drive outlook.1COV
Q4 20247 Jan 2026 - AGM approved all proposals amid a challenging year, XRG partnership, and no dividend for 2024.1COV
AGM 20252 Dec 2025 - Q1 sales steady, EBITDA fell on one-offs; 2025 outlook narrowed as transformation and XRG progress.1COV
Q1 202525 Nov 2025